C4 Therapeutics (NASDAQ:CCCC) Hits New 1-Year Low at $26.23

C4 Therapeutics, Inc. (NASDAQ:CCCC)’s share price reached a new 52-week low during trading on Friday . The company traded as low as $26.23 and last traded at $26.40, with a volume of 4483 shares changing hands. The stock had previously closed at $27.04.

A number of equities research analysts have commented on the company. Stifel Nicolaus initiated coverage on C4 Therapeutics in a report on Wednesday, September 29th. They issued a “hold” rating and a $45.00 target price for the company. SVB Leerink initiated coverage on C4 Therapeutics in a research note on Thursday, October 14th. They set a “market perform” rating and a $20.00 price target for the company. Zacks Investment Research downgraded C4 Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Bank of America started coverage on C4 Therapeutics in a research note on Tuesday, November 23rd. They set a “buy” rating and a $54.00 price target for the company. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $46.57.

The company has a quick ratio of 8.47, a current ratio of 8.47 and a debt-to-equity ratio of 0.03. The firm has a fifty day simple moving average of $35.24 and a 200 day simple moving average of $40.00.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings results on Wednesday, November 10th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.06. The company had revenue of $8.50 million during the quarter, compared to analysts’ expectations of $7.28 million. C4 Therapeutics had a negative return on equity of 26.49% and a negative net margin of 265.03%. As a group, equities research analysts forecast that C4 Therapeutics, Inc. will post -2.11 earnings per share for the current fiscal year.

In other C4 Therapeutics news, Director Malcolm Salter sold 755 shares of C4 Therapeutics stock in a transaction dated Friday, November 19th. The stock was sold at an average price of $40.11, for a total value of $30,283.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 21.04% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its holdings in C4 Therapeutics by 69.0% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,544,837 shares of the company’s stock valued at $134,137,000 after buying an additional 1,447,028 shares during the period. BlackRock Inc. grew its holdings in shares of C4 Therapeutics by 19.9% during the 3rd quarter. BlackRock Inc. now owns 3,157,207 shares of the company’s stock worth $141,064,000 after purchasing an additional 524,783 shares during the period. RTW Investments LP grew its holdings in shares of C4 Therapeutics by 16.1% during the 3rd quarter. RTW Investments LP now owns 2,494,965 shares of the company’s stock worth $111,475,000 after purchasing an additional 345,737 shares during the period. ArrowMark Colorado Holdings LLC grew its holdings in shares of C4 Therapeutics by 8.5% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,514,620 shares of the company’s stock worth $67,673,000 after purchasing an additional 118,999 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of C4 Therapeutics by 262.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,406,840 shares of the company’s stock worth $53,234,000 after purchasing an additional 1,018,882 shares during the period. Institutional investors own 70.95% of the company’s stock.

C4 Therapeutics Company Profile (NASDAQ:CCCC)

C4 Therapeutics, Inc, a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.

Further Reading: How do CD ladders protect against rising interest rates?

Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.